SCHEDULE 13D/A: Key Insider-Affiliated Foundation Boosts Stake in CASI Pharmaceuticals

Huiying Memorial Foundation, a private family foundation associated with CASI Pharmaceuticals' founder, Dr. Wei-Wu He, has increased its beneficial ownership in the company through an open market purchase of 357,644 ordinary shares.

Summary

• This document is Amendment No. 9 to the Schedule 13D filing for CASI Pharmaceuticals, Inc., updating beneficial ownership information.
• On June 16, 2025, Huiying Memorial Foundation purchased 357,644 Ordinary Shares from the open market.
• The total cost of this acquisition was $668,371, with per share prices ranging from US$1.3288 to US$2.088, funded by Huiying Memorial Foundation's personal funds.
• As of June 20, 2025, CASI Pharmaceuticals, Inc. has 15,506,348 Ordinary Shares outstanding.
• Dr. Wei-Wu He, Ph.D., the founder and managing partner of related entities, beneficially owns an aggregate of 3,735,535 shares, representing 23.8% of the class, which includes 220,000 shares issuable upon option exercise.
• Huiying Memorial Foundation's beneficial ownership stands at 407,644 shares, accounting for 2.6% of the class.
• Other reporting persons include Emerging Technology Partners, LLC (1,097,341 shares, 7.1%), ETP Global Fund L.P. (753,234 shares, 4.9%), ETP BIOHEALTH III FUND, L.P. (300,000 shares, 1.9%), and HE Family GRAT (100,000 shares, 0.6%).

Sentiment

Score: 7

Explanation: The sentiment is positive due to the significant share purchase by a foundation closely associated with a key insider, indicating confidence in the company. No negative information or risks were disclosed in this filing.

Positives

• The purchase of additional shares by Huiying Memorial Foundation, a foundation associated with a key insider (Dr. Wei-Wu He), signals strong confidence in CASI Pharmaceuticals' future prospects.
• Increased beneficial ownership by a related party can be interpreted as a positive indicator of long-term commitment and alignment of interests with the company's success.

Future Outlook

This Schedule 13D amendment does not contain explicit forward-looking statements or guidance regarding the company's future operations or financial performance, focusing solely on changes in beneficial ownership.

Management Comments

• Dr. Wei-Wu He, Ph.D., disclaims beneficial ownership of Huiying Memorial Foundation's shares of the Issuer for any purpose, stating that he does not participate in the investment decisions of the Foundation with respect to the Issuer's shares, despite being an officer and having family members on the Board of Trustees.

Industry Context

This filing is an ownership disclosure and does not provide specific details on broader industry trends or competitive landscape. However, increased insider-affiliated ownership in a pharmaceutical company can signal confidence in its drug pipeline or market position within the biotech sector.

Related Party Transactions

• Huiying Memorial Foundation, a 501(c)(3) private family foundation, purchased 357,644 Ordinary Shares from the open market for $668,371. Dr. Wei-Wu He, Ph.D., a reporting person, is an officer of the Foundation, and family members are on its Board of Trustees, making this a related party transaction, although Dr. He disclaims beneficial ownership for investment decisions.

Stakeholder Impact

• Shareholders: The increased stake by an insider-affiliated entity may instill greater confidence among existing and potential shareholders, potentially leading to positive market perception.
• Management: The transaction reinforces the alignment of interests between the company's leadership (via Dr. He's association) and shareholder value.

Key Dates

Recommendation

Keywords

CASI Pharmaceuticals, Schedule 13D, Beneficial Ownership, Insider Buying, Share Purchase, Huiying Memorial Foundation, Wei-Wu He, SEC Filing, Biotechnology, Pharmaceuticals, Investment, Equity Stake